)
)
Infant Bacterial Therapeutics Investor Relations Material
Latest events
Study Update
Infant Bacterial Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics AB, a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company focuses on late onset neonatal infection, a disease caused by an imbalance in the infant’s gut microbiota. Its lead drug candidate is IBP-9414 is being developed for the treatment of lactobacillus plantarum, enterococcus faecium and escherichia coli infections in preterm infants. The company was formerly known as Enterome AB and changed its name to Infant Bacterial Therapeutics AB in August 2012. Infant Bacterial Therapeutics AB is based in Stockholm, Sweden. As of March 4, 2015, Infant Bacterial Therapeutics AB operates as a subsidiary of Tim Medical Holdings Limited.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
IBT
Country
🇸🇪 Sweden